Sunovion Pharmaceuticals Inc. today announced results from a new pooled data analysis on weight and metabolic parameters across short- and long-term studies in adult patients with schizophrenia treated with Latudaź (lurasidone HCl) tablets. These data were presented at the Annual Meeting of the American Psychiatric Association in Honolulu, Hawaii...

More...